Table 1 The clinical characteristics in training, test and total sets
From: Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer
Variables | Type | Total set (n = 502) | Test set (n = 251) | Training set (n = 251) | P value |
|---|---|---|---|---|---|
Age |  ≤ 60 | 389 (77.49%) | 198 (78.88%) | 191 (76.1%) | 0.5214 |
 > 60 | 113 (22.51%) | 53 (21.12%) | 60 (23.9%) | ||
Gender | Female | 367 (73.11%) | 184 (73.31%) | 183 (72.91%) | 1 |
Male | 135 (26.89%) | 67 (26.69%) | 68 (27.09%) | ||
Stage | Stage I–II | 333 (66.33%) | 174 (69.32%) | 159 (63.35%) | 0.2297 |
Stage III–IV | 167 (33.27%) | 77 (30.68%) | 90 (35.86%) | ||
Unknow | 2 (0.4%) | 0 (0%) | 2 (0.8%) | ||
T | T1-2 | 307 (61.16%) | 164 (65.34%) | 143 (56.97%) | 0.0662 |
T3-4 | 193 (38.45%) | 86 (34.26%) | 107 (42.63%) | ||
Unknow | 2 (0.4%) | 1 (0.4%) | 1 (0.4%) | ||
M | M0 | 282 (56.18%) | 137 (54.58%) | 145 (57.77%) | 0.9415 |
M1 | 9 (1.79%) | 5 (1.99%) | 4 (1.59%) | ||
Unknow | 211 (42.03%) | 109 (43.43%) | 102 (40.64%) | ||
N | N0 | 229 (45.62%) | 112 (44.62%) | 117 (46.61%) | 0.7067 |
N1 | 223 (44.42%) | 114 (45.42%) | 109 (43.43%) | ||
Unknow | 50 (9.96%) | 25 (9.96%) | 25 (9.96%) |